TG Therapeutics, Inc.
TGTXNASDAQHealthcare● Active
$41.11
+$0.95(+2.35%)
Market Cap$6.3B
P/E Ratio—
52W High$44.65
52W Low$25.28
TG Therapeutics, Inc. (TGTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TGTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.62B | $0.33B | $0.23B | $0.00B | $0.01B |
| Cost of Revenue | $0.10B | $0.04B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.52B | $0.29B | $0.22B | $0.00B | $0.01B |
| Gross Margin %(computed) | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% |
| Operating Expenses | |||||
| R&D Expenses | $0.16B | $0.09B | $0.08B | $0.13B | $0.22B |
| G&A Expenses | $0.23B | $0.15B | $0.12B | $0.10B | $0.13B |
| Total Operating Expenses | $0.39B | $0.25B | $0.20B | $0.22B | $0.35B |
| Operating Income | $0.12B | $0.04B | $0.02B | ($0.22B) | ($0.34B) |
| Operating Margin %(computed) | 20.01% | 12.74% | 8.83% | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.02B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.11B | $0.03B | $0.01B | ($0.22B) | ($0.35B) |
| Income Tax Expense | ($0.34B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.45B | $0.02B | $0.01B | ($0.22B) | ($0.35B) |
| Net Margin %(computed) | 72.56% | 7.11% | 5.42% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.10 | $0.16 | $0.09 | $-1.46 | $-2.63 |
| Wtd Avg Shares | 0.14B | 0.15B | 0.14B | 0.14B | 0.13B |
| EBITDA | $0.13B | $0.05B | $0.03B | ($0.21B) | ($0.34B) |
| EBITDA Margin %(computed) | 21.80% | 15.17% | 11.17% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more TG Therapeutics, Inc. data
About TG Therapeutics, Inc. (TGTX) Income Statement
TG Therapeutics, Inc. (TGTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TGTX reported revenue of $0.62B, gross profit of $0.52B (gross margin 83.66%), and net income of $0.45B — a net profit margin of 72.56%.
Frequently asked questions
TGTX · 4 questionsTG Therapeutics, Inc. (TGTX) reported revenue of $0.62B for 2025, up 87.3% year-over-year.
TGTX revenueTGTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08